Evidence map›Paper›PMID 40606812›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2025

Comorbidities and Cause of Death in COPD Patients Compared to Non-COPD Controls: An 8-year Observational Retrospective Healthcare Claims Database Cohort Study.

Claus F Vogelmeier, Felix W Friedrich, Patrick Timpel, Nils Kossack, Joanna Diesing, Marc Pignot, Melanie Abram, Michael Gediga, Marija Halbach

Abstract readObservational Study
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Claus F VogelmeierDepartment of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, German Center for Lung Research (DZL), Marburg, Hessen, Germany.
Felix W FriedrichAstraZeneca GmbH, Hamburg, Germany.ORCID 0000-0002-8400-9445
Patrick TimpelWIG2 GmbH Scientific Institute for Health Economics and Health System Research, Leipzig, Saxony, Germany.
Nils KossackWIG2 GmbH Scientific Institute for Health Economics and Health System Research, Leipzig, Saxony, Germany.
Joanna DiesingWIG2 GmbH Scientific Institute for Health Economics and Health System Research, Leipzig, Saxony, Germany.ORCID 0000-0001-5809-583X
Marc PignotZEG - Center for Epidemiology and Health Research Berlin GmbH, Berlin, Germany.ORCID 0000-0002-1883-4113
Melanie AbramAstraZeneca GmbH, Hamburg, Germany.
Michael GedigaAstraZeneca GmbH, Hamburg, Germany.
Marija HalbachAstraZeneca GmbH, Hamburg, Germany.

Funding

Aerogen, AstraZeneca, Boehringer Ingelheim,Aerogen, Sanofi, and RocheAstraZenecaCSL Behring, Chiesi,GlaxoSmithKline, Grifols,Insmed, Menarini,Novartis, Nuvaira, MedUpdate,
6 · The paper itself

Abstract

Purpose: Patients with COPD suffer from various comorbidities, seemingly leading to a collective increase in morbidity and mortality. However, comorbidities with COPD have been largely unreported. Patients and Methods: Using healthcare claims data, only the deceased among around 250,000 COPD patients diagnosed in 2011-2018 were evaluated by cause of death (cumulative incidence without competing risk) across a period of up to eight years. Results were compared with 1:1 propensity score-matched controls. Additionally, the prevalence of comorbidities in deceased patients was compared. Results: On average, deceased COPD patients and matched controls lived to be 75.7 and 78.0 years, respectively, and COPD patients had more comorbidities prior to death (mean 4.53 and 3.65). Both respiratory and cardiovascular-related deaths were more likely in COPD patients than in their matched controls (3.3 and 1.6 percentage points higher after eight years), and this was more extreme (9.8 and 3.4 percentage points higher, respectively) in the COPD subgroup with multiple/severe exacerbations; cumulative incidence of death increased with increasing COPD severity. Comorbidity prevalence, especially cardiovascular-related, was higher in COPD patients than in matched controls; COPD patients had a 42% higher risk of heart failure (RR 1.42; 1.38-1.47), 30% higher risk of ischemic heart disease (RR 1.30; 1.25-1.35), and 27% increased risk of atrial fibrillation (RR 1.27; 1.21-1.32). Conclusion: In this real-world observational retrospective cohort study, we found patients with COPD died at a younger age, and developed more comorbidities, than matched controls.

Indexed as

Cardiovascular DiseasesPulmonary Disease, Chronic ObstructiveAdministrative Claims, HealthcareAgedAged, 80 and overCause of DeathComorbidityDatabases, FactualFemaleHumansIncidenceMaleMiddle AgedPrevalenceRetrospective StudiesRisk Assessmentcardiovascular deathcardiovascular diseaseexacerbationsmortalitymultimorbidityrespiratory death

Identifiers

PMID40606812
PMCPMC12214430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.